TLDR
- Piper Sandler upgraded Tempus AI from Neutral to Overweight, raising its price target from $56 to $76
- TEM stock rose around 2.1-2.5% in premarket trading Tuesday
- The analyst cited three growth drivers: the Personalis acquisition, a positive INTerpath-001 study readout, and FDA approval of the xT CDx test
- The Personalis deal values each share at $16.25, paid in Tempus Class A stock, with Tempus able to elect cash for up to half the stock
- Canaccord Genuity reiterated a Buy rating at $80 following the S-4 filing on August 31
Tempus AI (TEM) climbed between 2.1% and 2.5% in premarket trading Tuesday after Piper Sandler analyst David Westenberg upgraded the stock from Neutral to Overweight and raised his price target to $76 from $56.
The upgrade marks a shift in how Westenberg views the stock. His previous Neutral rating was based on the view that TEM’s valuation was being driven by AI sentiment rather than the actual performance of its diagnostics and data businesses.
That view has now changed. Westenberg said three growth drivers have become increasingly visible, giving him more confidence in the company’s fundamentals.
The first driver is the pending acquisition of Personalis. Through this deal, Tempus will gain ownership of a tumor-informed minimal residual disease (MRD) platform, which Piper Sandler sees as a differentiated asset in the oncology diagnostics space.
The S-4 for the deal was filed on August 31. It outlines terms that value each Personalis share at $16.25, to be paid in Tempus Class A stock at a ratio tied to the Tempus share price. Tempus also has the option to pay cash for up to half of the stock.
INTerpath-001 Readout Adds Strategic Value
The second driver is the positive readout from the INTerpath-001 study. Westenberg said this increases the strategic value of both Personalis and Tempus AI as the tumor sequencing provider for what could become a new therapeutic class.
That readout strengthens Tempus’s position in the MRD space at a time when the Personalis deal is still pending, giving the company a clearer path forward in the clinical sequencing market.
FDA Clears Key Hurdle for xT CDx
The third driver is FDA approval of the tumor-only xT CDx test. Piper Sandler said this clears a key hurdle for Tempus to pursue unified ADLT pricing for its xT product line.
The analyst added that xF, a related product, could follow a similar regulatory path in the second half of 2027. Unified ADLT pricing would have a direct impact on Tempus’s revenue model for these tests.
Canaccord Genuity also weighed in following the S-4 filing on August 31, reiterating its Buy rating on TEM with a price target of $80.
That puts Canaccord slightly above Piper Sandler’s new $76 target, with both firms now holding positive ratings on the stock.
The S-4 filing on August 31 remains the most recent formal disclosure related to the Personalis transaction, with deal terms now publicly available for investors to review.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
